Glp3-Reta

Last updated: April 21, 2026

Quick Answer

Glp3-Reta is a triple-receptor agonist research peptide that simultaneously targets GLP-1, GIP, and glucagon receptors. Unlike single or dual agonists, this compound activates three metabolic pathways at once, which has generated significant interest among researchers studying body composition, energy expenditure, and metabolic flexibility. It is currently used in preclinical and in-vitro research settings, not approved for human therapeutic use.

Key Takeaways

  • Glp3-Reta is a triple agonist — it engages GLP-1, GIP, and glucagon receptors simultaneously.
  • Triple agonism differs from dual agonism by adding glucagon receptor activation, which may increase energy expenditure in research models.
  • Research interest has surged since 2024 as scientists explore multi-receptor approaches beyond tirzepatide-class dual agonists.
  • Peptide purity matters — sourcing from manufacturers with third-party testing and certificates of analysis (COA) is essential for valid research.
  • Storage requirements are strict — lyophilized Glp3-Reta should be kept at -20°C before reconstitution and 2-8°C after.
  • This compound is for research purposes only and is not approved by the FDA for human use.
  • Dosing protocols in published literature vary widely depending on the animal model and study endpoints.
  • The incretin pathway (GLP-1 and GIP) is the foundation of this peptide’s mechanism, with glucagon adding a thermogenic component.